Hatieganu", Cluj-Napoca, Romania. Abstract Aim: to evaluate the therapeutic efficacy of oxaliplatin and to analyze the pharmacokinetics of both ultrafiltrable free and protein-bound platinum in patients with metastatic colon cancer.
Method: 60 patients with stage IV colon carcinoma received mean 4. Response rate, progression-free survival PFS and toxicity were evaluated.
The median time of progression was 9. Cumulative neurotoxicity, vomiting and diarrhea, myelosuppression appeared in The mean Cmax and AUC of oxaliplatin increased cancer colon diarrhea a dose-related manner. The pharmacokinetics of platinum after oxaliplatin administration was triphasic characterized by a short initial distribution phase and a long terminal elimination phase.
The clearance of ultrafiltrable platinum was relatively high and cancer colon diarrhea clearance of platinum from plasma and blood cells was relatively low, which is probably a reflection of the covalent binding of platinum to these matrices.
Conclusion: Oxaliplatin is active and well tolerated in patients with advanced colon cancer.
With a relatively low interpatient variability, it is eliminated triphasically and the mean Cmax and AUC increases in a dose-related manner. These results provide a scientific basis for the safe and effective use of oxaliplatin in the clinic.